Galectin Therapeutics Inc. (NASDAQ: GALT) is a Healthcare company (Biotechnology) with a market capitalization of $192M. The Maz Rating grades it against the other companies in its sector.
Galectin Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Galectin Therapeutics Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 21.7%, return on invested capital of 9066.7% and a free cash flow yield of -7.6%. On the balance sheet: a debt-to-equity ratio of -0.95 and a current ratio of 0.28. Over the past 52 weeks the share price ranged from $2.03 to $7.13, with a beta of 0.38.
Galectin Therapeutics Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Galectin Therapeutics Inc. (GALT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.73% / 30% · Interest income / Revenue 2800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 13.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.73% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 2800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 13.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.73% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 2800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 697.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.0% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 2800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 255.3% / 33.33% · (Cash+ST Inv) / Total Assets 90.0% / 33.33% · (Cash+Recv) / Total Assets 90.0% / 33.33% · Interest income / Revenue 2800000.0% / 5% | Fail |
No. As of September 2026, Galectin Therapeutics Inc. (GALT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Galectin Therapeutics Inc. is over the AAOIFI limit on Interest income / Revenue.
About 2800000.0% of each dividend: Galectin Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.